H. pylori Treatment Recommendation
For first-line empiric treatment of H. pylori infection, use either bismuth quadruple therapy (PPI + bismuth + metronidazole + tetracycline) or concomitant non-bismuth quadruple therapy (PPI + amoxicillin + clarithromycin + metronidazole) for 14 days. 1
First-Line Treatment Options
The most recent 2022 guidelines establish two primary empiric regimens that achieve >85-90% eradication rates 1, 2:
Bismuth Quadruple Therapy (PBMT) - 14 days:
- PPI (esomeprazole or rabeprazole 20-40 mg) twice daily, 30 minutes before meals
- Bismuth subsalicylate 2 tablets four times daily, 30 minutes before meals
- Tetracycline 500 mg four times daily, 30 minutes after meals
- Metronidazole 500 mg four times daily, 30 minutes after meals
This regimen achieved 88.3% eradication in a large U.S. community study without substantial decline over time 2. It remains effective even with metronidazole-resistant strains due to bismuth's synergistic effect 3.
Concomitant Non-Bismuth Quadruple Therapy (PAMC) - 14 days:
- PPI (esomeprazole or rabeprazole 20-40 mg) twice daily
- Amoxicillin 1000 mg twice daily
- Clarithromycin 500 mg twice daily
- Metronidazole 500 mg twice daily
This achieved 89.8% eradication in the same U.S. study 2 and is recommended by all major guidelines 3, 4.
Critical PPI Selection
Avoid pantoprazole. Use esomeprazole 20-40 mg or rabeprazole 20-40 mg twice daily, as these are the most potent PPIs 1. The relative potency matters significantly: 20 mg esomeprazole = 32 mg omeprazole, while 40 mg pantoprazole = only 9 mg omeprazole.
Obsolete Regimens to Avoid
Do not use sequential, hybrid, or reverse hybrid therapies—these are explicitly labeled as obsolete because they include antibiotics offering no therapeutic benefit while increasing antimicrobial resistance 1.
Clarithromycin triple therapy (PPI + clarithromycin + amoxicillin) should only be used if local susceptibility testing confirms >90% cure rates or in areas with documented low clarithromycin resistance 1, 3.
Salvage (Second-Line) Treatment
After first-line failure, bismuth quadruple therapy achieved the highest salvage eradication rate (69.3%) in real-world U.S. data 2.
Alternative Salvage Options:
Rifabutin Triple Therapy - 14 days:
- Rifabutin 150 mg twice daily
- Amoxicillin 1000 mg three times daily
- Esomeprazole or rabeprazole 40 mg twice daily, 30 minutes before meals
This is reserved for patients who have failed 2-3 prior regimens 1, 3.
Levofloxacin Triple Therapy - 14 days (if fluoroquinolone resistance is low):
- Levofloxacin 500 mg once daily
- Amoxicillin 1000 mg twice daily
- PPI twice daily
However, the FDA recommends fluoroquinolones as last-choice due to serious side effects 1.
Critical Treatment Principles
Never repeat previously failed antibiotics, especially clarithromycin or levofloxacin, where resistance develops rapidly after exposure 3, 2. Repeating the same regimen reduces eradication rates by 50% (adjusted OR 0.46-0.51) 2.
Review antibiotic history: Prior macrolide use reduces clarithromycin-containing regimen success by 32% (aOR 0.68), and prior metronidazole use reduces metronidazole-containing regimen success by 39% (aOR 0.61) 2.
Duration matters: All regimens should be 14 days. The 2022 guidelines emphasize that shorter durations compromise eradication rates 1, 4.
Penicillin Allergy
For true penicillin allergy, use bismuth quadruple therapy as the preferred option 3, 4. Clarithromycin-metronidazole triple therapy is inferior and should be avoided unless susceptibility testing confirms low resistance.
Treatment Paradigm Shift
The 2022 guidelines represent a fundamental shift: H. pylori should be treated as an infectious disease targeting ≥95% cure rates, not as a typical GI condition with modest success 1. The goal is to succeed on the first attempt, avoiding retreatment cycles that increase resistance and reduce subsequent cure rates.